Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S

[Farooqji]

stocktitan.net/news/AMRX/am...

[park_bear]

Amneal Pharmaceuticals (NASDAQ: AMRX) announced expanded insurance coverage for CREXONT®, its Parkinson's disease treatment, with three major insurers: Veterans Administration, UnitedHealthcare, and CVS Health. This expansion increases total U.S. coverage from 30% to over 50% of covered lives, achieved nine months ahead of their end-2025 target.

CREXONT, FDA-approved in August 2024, combines immediate-release granules with extended-release pellets, making it the longest-lasting oral carbidopa/levodopa formulation available. Clinical trials demonstrated 1.55 more hours of 'Good On' time per dose compared to immediate-release alternatives, representing a 70% increase in symptom control time.

The coverage rollout includes: VA's immediate national formulary addition (covering ~10% of U.S. PD patients), UnitedHealthcare's addition in Q2 2025, and CVS Health's inclusion as a 'preferred' product starting July 1, 2025.

[Ctime]

Tremendous. Just what the world needs now, a new patented and expensive version of Carbidopa Levodopa carefully designed to increase health care costs and put a checkbox on the "new treatments developed" line while providing very marginal benefits.